Tagged with Italy

Pharma The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s rich pipeline is set to boost growth in new areas over the next few years. We interviewed you during your…

Pharma The CEO of MSD Italy discusses the company’s promising pipeline, its plans to realize growth through the launch of innovative new drugs in 2016, the paths towards a sustainable healthcare system for Italy, and the vision she has for her company. At the beginning of the New Year, how is…

Pharma The MD of the Spanish Chamber of Commerce in Italy takes stock of the prevailing business winds between the two countries as both economies complete their emergence from the shadow of the global financial crisis. Citing the important contribution of entities such as Banca Farmafactoring in providing liquidity to pharmaceutical and…

Pharma Massimo Visentin, Country Leader for Pfizer Italy, discusses the company’s remarkable success in 2015, his hopes and ambitions for the new year, and the need of the industry and Pfizer specifically to engage the government in the development of a more sustainable healthcare system. To start off, we are approaching…

Pharma Prof. Luigi Naldini, Director of TIGET, discusses the success of the institute and the groundbreaking partnerships it has formed with the pharmaceutical industry, as well as his ambitions for TIGET over the coming years. Prof. Naldini, the San Raffaele Telethon Institute for Gene Therapy was set up in 1995 as…

Pharma Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics of the Italian market that make it especially promising to Celgene. Mr. Frega, to start off, Imnovid, Celgene’s newest oral treatment…

Pharma Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently being implemented in the regulatory system will have on the industry moving forward.   Dr. Piliounis, to start off, you…

Pharma Chris Juliam, Managing Director for Takeda Italy, shares the strategy the company is pursuing in the country, the effects market-access issues are having on innovators and patients, and what new products the company’s pipeline holds for the future. When we interviewed Takeda in 2009, you were ranked 20th in the…

Pharma Prof. Manuela Battaglia (MB) and  Prof. Lorenzo Piemonti (LP) discuss the positioning of the Diabetes Research Institute (DRI) within the San Raffaele Scientific Institute and the global diabetes care community, their respective specialty areas and DRI’s commitment to translational medicine. The Diabetes Research Institute (DRI) is part of the International…

Pharma Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees emerging and the market environment for generics companies in Italy today. When we last spoke in 2009, you told us…

Pharma Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities; how they will look to continue to establish themselves in their three main areas: respiratory diseases,…

Pharma CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries, and her optimism about Italy’s return to economic growth. Ms Zanardi, you have been at the head of the CFCII…